Immune Markers of Anti-BCMA CAR-T in Myeloma
In recent years, the landscape of multiple myeloma treatment has witnessed transformative advances, notably with the emergence of chimeric antigen receptor T-cell (CAR-T) therapies targeting the B-cell maturation antigen (BCMA). A groundbreaking study published in Nature Communications by Atanackovic et al. delves deeply into the intricate immune correlates associated with two FDA-approved anti-BCMA CAR-T products: […]
In recent years, the landscape of multiple myeloma treatment has witnessed transformative advances, notably with the emergence of chimeric antigen receptor T-cell (CAR-T) therapies targeting the B-cell maturation antigen (BCMA). A groundbreaking study published in Nature Communications by Atanackovic et al. delves deeply into the intricate immune correlates associated with two FDA-approved anti-BCMA CAR-T products: […]
What's Your Reaction?
